Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
|
|
Wall Street Journal - February 9, 2007
The government-backed South African AIDS Vaccine Initiative said the trial will be conducted on 3,000 HIV-negative people from 18 to 35 years old. It will test whether the MRKAd5 HIV-1 vaccine developed by Merck & Co. either prevents HIV infection or lowers HIV levels in those who become infected.
It will also measure the effectiveness of the drug on the C strain of HIV prevalent in South Africa, whose population of 45 million has an HIV infection rate of around one in nine.
070209
WJ070202
Copyright © 2007 - The Wall Street Journal. Reproduction of this article (other than one copy for personal reference) must be cleared through the WSJ Permissions Desk.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .